- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07643467
Fluorescent Probe for Assessment of Renal Elimination (FLARE)
Descripción general del estudio
Estado
Condiciones
Descripción detallada
The majority of acutely ill patients exhibit changes in renal function due to inflammation, increased solute generation, and iatrogenic factors such as fluid resuscitation and vasopressors. The pharmacokinetics of renally eliminated medications (eg. levetiracetam, cefepime, vancomycin) are frequently affected by inflammatory processes despite normal estimations in creatinine clearance resulting in suboptimal serum drug concentrations and therapeutic failure. Despite the prevalence of fluctuations in renal function in acute illness, real-time assessment is limited to monitoring of serum biomarkers such as creatinine and cystatin C, as well as urine output, which typically lag behind important changes in function. Furthermore, use of creatinine clearance equations based on anthropomorphic data correlates poorly with actual renal function, potentially misleading clinicians as to the progression of disease and the need for dose adjustment of important medications in this vulnerable population.
Limitations of current approaches for evaluating renal function in the acutely ill Estimation of GFR or creatinine clearance can be accomplished by numerous equations, the majority of which have been validated in non-critically ill adults, usually with a relatively high percent of patients with chronic kidney disease. These equations are often not accurate in patients with acutely worsening renal function. Likewise, while these equations are helpful for categorizing renal function and assessing appropriate medication dosing in otherwise healthy, ambulatory patients. Under-prediction of creatinine clearance values leads clinicians to consistently under-dose critical medications such as beta-lactam antibiotics, vancomycin, or antiseizure medications such as levetiracetam.
Proactive measurement of creatinine clearance can provide a more accurate depiction of GFR but is fraught with complications. Iohexol serum concentrations correlate well with GFR, but requires intravenous administration of iohexol, which has a small risk of infusion reaction and hypersensitivity, and serial blood samples. Measured urine creatinine clearance is also feasible but inconvenient in most hospitalized patients. mClCr requires bladder catheterization for accurate urine volume, consistent storage on ice for the duration of collection (between 8 and 24 hours), and prompt delivery of the large volume container to the local laboratory for creatinine analysis. Each of these criteria introduce variability into the measurement and are often unnoticed or undocumented, introducing inaccuracy into the mClCr values. The lack of a real-time, accurate assessment of creatinine clearance in the acutely ill population is a gap in practice and represents a resolvable problem in the process of individualized and precision dosing of medications in this vulnerable and high-risk population.
This study represents an important innovation in advancing the understanding of fluctuations in renal function during acute illness. The current study will validate the safety of transdermal GFR monitoring to provide real-time measurement of renal function in patients with stable renal function. Further, the reliability of transdermal GFR monitoring will be compared to current standards of renal function assessment. The results of this study will advance the field by validating the use of a real-time physiologic assessment of GFR rather than using labor intensive, invasive tests that may lag behind current renal function. Numerous important gaps remain with this new technology, including use primarily in the ambulatory, stable renal function populations. Thus, this study is potentially the first step in evaluating renal function across the acute care continuum.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 4
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Aaron Cook, PharmD
- Número de teléfono: 18592578444
- Correo electrónico: amcook0@uky.edu
Ubicaciones de estudio
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos, 40536
- UKHealthCare/University of Kentucky
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- 18-65 years old
- critically ill or acutely ill hospitalized patients admitted to the intensive care unit
- Stable/normal renal function
Exclusion Criteria:
- Prisoners
- Pregnant women
- Laboratory evidence of unstable kidney function (KDIGO AKI stage 1-3--This includes subjects with Scr > 1.5x baseline)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Diagnóstico
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: MediBeacon Transdermal Glomerular Filtration Rate (GFR) Monitoring
|
IV push of relmapirazin (Lumitrace) prior to use of the tGFR device
Small IV push bolus of iohexol as a probe for renal function will be administered prior to use of the tGFR device.
The tGFR monitor will be applied to the patient after relmapirazin bolus for measurement of GFR.
8-hour urine creatinine clearance collection will be performed during the study period to compare to tGFR & other renal function measures.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Transdermal Glomerular Filtration Rate (tGFR) Monitoring Accuracy
Periodo de tiempo: 8 Hours
|
Accuracy of transdermal glomerular filtration rate (GFR) monitoring compared with measured urine creatinine clearance.
|
8 Hours
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Relmapirazin Elimination Half-Life
Periodo de tiempo: 12 hours
|
Elimination half-life of Relmapirazin calculated from serial serum concentration measurements obtained over 12 hours following intravenous administration.
|
12 hours
|
|
Iohexol Elimination Half-Life
Periodo de tiempo: 12 hours
|
Elimination half-life of Iohexol calculated from serial serum concentration measurements obtained over 12 hours following intravenous administration.
|
12 hours
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Aaron M Cook, PharmD, University of Kentucky College of Pharmacy, Department of Pharmacy Practice & Science
- Director de estudio: Juan-Carlos Aycinena, MD, University of Kentucky College of Medicine, Department of Nephrology
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Atributos de la enfermedad
- Condiciones Patológicas, Signos y Síntomas
- Enfermedad crítica
- Químicos orgánicos
- Hidrocarburos
- Hidrocarburos, cíclico
- Ácidos carboxílicos
- Hidrocarburos, aromáticos
- Derivados de benceno
- Ácidos, carbocíclicos
- Benzoates
- Ácidos triodobenzoicos
- Yodobenzoates
- Iohexol
- relmapirazin
Otros números de identificación del estudio
- 105008
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .